Core Insights - The Science and Technology Innovation Board (STAR Market) has fostered an environment for innovation and entrepreneurship over the past six years, attracting high-level scientific talent and facilitating the transformation of innovative advantages into industrial and national competitive advantages [1][2] Group 1: Talent and Innovation - Over 60% of STAR Market companies have founding teams composed of scientists, engineers, or industry experts, with nearly 40% establishing partnerships with universities and research institutions [1] - A significant number of STAR Market companies are led by individuals with academic backgrounds, including 75 companies with leaders who have experience as university professors or doctoral advisors [2][4] - More than 30% of STAR Market company leaders have overseas study experiences, particularly in the fields of biomedicine and integrated circuits, where this figure rises to 50% [3] Group 2: Industry Collaboration - STAR Market companies have achieved over 1,100 collaborative projects that have led to the industrialization of research outcomes in the past three years [1][6] - Approximately 80% of STAR Market companies engage in industry-academia-research collaborations, with over 70% partnering with 985/211 universities or Chinese Academy of Sciences research institutions [6] - The collaboration has resulted in over 4000 projects, with more than 1300 receiving national or provincial-level funding, and 1100 projects achieving industrialization [6] Group 3: Intellectual Property and R&D - STAR Market companies have collectively generated over 120,000 invention patents, with more than 20,000 new patents filed in 2024 alone [7] - The STAR Market has implemented adaptive equity incentive systems to attract and retain talent, with over 70% of companies utilizing these tools, covering more than 140,000 core business and technical personnel [7] - The total number of R&D personnel in STAR Market companies exceeds 240,000, accounting for nearly 30% of the total workforce [7]

过去几年，联影高端医疗装备陆续破冰美、日、欧等海外高端市场，产品进驻美国、日本、意大利、新西兰、波兰、印度、韩国等超85个国家和地区。 这些国产高端医疗装备背后，是联影打造的业内唯一覆盖"整机系统-核心部件-关键元器件"垂直创新体系。据介绍，联影已实现了PET数字光导探测器、MR 超导磁体、谱仪、梯度功率放大器、射频功率放大器、CT时空探测器、球管、X光高压发生器、RT多叶光栅、加速管等全线高端医学影像及放疗产品核心 部件的自主研发，核心部件自研比例全球领先。 北京商报讯（记者 徐慧）像DeepSeek惊艳全球一样，在高端医疗装备领域，中国智造正在跻身世界一流。在4月22日举行的2025年服贸会"高管谈服贸"系列 采访活动上，联影医疗中国区副总裁李晶珏介绍，联影已推出一批掌握完全自主知识产权的"世界首款""中国首款"高端医疗装备，部分产品和技术实现世界 范围内的引领。目前，联影正以前瞻性布局，深度融合AI等技术，加速推动医疗服务业的数智化升级。 l ■ | 高 A UN it 随着中国智造的崛起，来自中国的高端医疗装备正在增进全球患者福祉。以联影在业界首创的CT一体化直线加速器为例，据介绍，该设备创新性地将放 ...